Why the study?
Do platelet glycoprotein IIb/IIIa antagonists improve outcomes in patients with coronary artery disease?
Population
Patients with coronary artery disease
Design
Review
Authors
Loading...
Synthesizes GP IIb/IIIa antagonist trials in CAD; leaves open their role in contemporary practice.
Do platelet glycoprotein IIb/IIIa antagonists improve outcomes in patients with coronary artery disease?
This review provides an overview of clinical trials investigating glycoprotein IIb/IIIa antagonists for the treatment of coronary artery disease.
Salam et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: